Posts Tagged ‘nasdaq’

Highway Holdings Limited (HIHO) higher profits boost stock price

Wednesday, June 29th, 2011

Highway Holdings Limited (Nasdaq:HIHO) shares vaulted 38.6% to $4.13, after the company reported net income for fiscal year 2011 climbed sharply to $1.7 million, or $0.44 per diluted share, from $420,000, or $0.11 per diluted share, in fiscal 2010. Volume for the stock totaled 261,123 shares, trouncing an all-day average of just over 4,600.

“Results for fiscal 2011 reflect a strongly improved business environment and the benefits of streamlining operations to enhance operating efficiencies,” according to CEO Roland Kohl, who in the June 29 press release, highlighted the two key strategic initiatives implemented during the past few years that have greatly enhance profitability; reducing the company’s operations from four factories to one, and the utilization of automation in its manufacturing process.

“As a consequence, the company was able to further improve its balance sheet and increase its cash position to take advantage of future strategic growth opportunities,” Kohl said.

Gross profits improved for both the fiscal 2011 fourth quarter and year — increasing by $367,000, or 26.16%, and $1,853,000, or 39.4%, respectively, compared with the same periods in fiscal 2010. Gross profit as a percentage of net sales remained essentially unchanged at approximately 21% percent for the fiscal year, despite initiatives noted above to reduce the company’s manufacturing expenses.

Highway Holdings produces a wide variety of high-quality products for blue chip original equipment manufacturers — from simple parts and components to sub-assemblies and finished products. Highway Holdings’ administrative offices are located in Hong Kong, and its manufacturing facilities are located in Shenzhen in the People’s Republic of China.

Payday lender Ezcorp Inc. (EZPW) rises on stock upgrade

Monday, June 27th, 2011

Pawn-shop operator and payday-loan chain Ezcorp Inc. (Nasdaq: EZPW) shares rose 7.1% late Monday to $34.33, after Sterne Agee analysts raised the stock to buy from neutral. Volume for the stock of 802,000 more than doubled its daily average.

According to a story Monday on Forbes.com, Sterne Agee Analyst Henry J. Coffey Jr. raised his rating on Ezcorp to “Buy” from “Neutral,” and boosted his forecast for the company’s 2012 earnings per share to $3 from $2.75. He also estimates Ezcorp will post earnings of $3.55 per share in 2013.

The site goes on to say that, despite the heightened scrutiny on payday lending, Ezcorp has seen continued growth in the U.S. and elsewhere, Coffey wrote in a research note Monday.

In March, the company announced a joint venture with Cash Converters that will push loans, pawn lending and other services in several international markets. In April, Ezcorp acquired the Canadian Cash Converters franchise. It also plans to reposition its Cash Max stores as Cash Converters and build out about 20 Cash Converter stores per year.

Based in Austin, Texas, EZCORP is a leading provider of specialty consumer financial services. It provides collateralized non-recourse loans, commonly known as pawn loans, and a variety of short-term consumer loans, including payday loans, installment loans and auto title loans, or fee-based credit services to customers seeking loans. At its pawn stores, the company also sells merchandise, primarily collateral forfeited from its pawn lending operations.

Icagen Inc. (ICGN) takes flight on hint of Pfizer takeover

Monday, June 27th, 2011

Icagen Inc. (Nasdaq: ICGN) shares rocketed 113.8% to $5.13 after drug manufacturer Pfizer Inc. (NYSE: PFE) said in a regulatory filing late Friday that it was looking at a possible strategic alliance with the biopharmaceutical company. Volume for Icagen totaled 1.8 million shares in the early trading hours of Monday, compared to an all-day average of 71,000.

A news release was issued soon after the market closed on Friday, June 24. In the release, Icagen put out a statement in which it acknowledged that it is currently engaged in preliminary discussions with Pfizer regarding a potential strategic transaction, but, quote “no definitive agreement has been reached.

“There can be no assurance that any agreement will be reached,” the statement continued, “or that a transaction will be consummated. Icagen does not plan to make future announcements with respect to this matter unless and until its Board of Directors has approved a specific transaction or an extension or other modification of the existing collaboration agreement and it has entered into a definitive agreement or the current discussions have terminated.”

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels.

Acura Pharmaceuticals (ACUR) rides FDA OK to stock surge

Monday, June 20th, 2011

Acura Pharmaceuticals (Nasdaq: ACUR) rose 19.4% to $4.62 on Monday, soon after the company said the U.S. Food and Drug Administration (FDA) had approved a pain treatment owned by Acura and Pfizer Inc. Volume for Acura stock topped 4.3 million, towering over a daily average of just below 168,000.

OXECTA is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common methods of tampering associated with opioid abuse and misuse. This AVERSION® Technology is a unique composition of commonly used pharmaceutical ingredients. Pfizer is licensing the technology in OXECTA from Acura.

Opioid medications are an important treatment option for patients with moderate to severe pain who are not adequately managed by other pain treatments. However, abuse and misuse of opioids is a serious public health issue that is the focus of a number of recent United States government initiatives.

In the June 20 press release trumpeting the approval from the federal body, interim Acura CEO Robert Jones said, “we are excited to be partnered with Pfizer to bring OXECTA to patients who need opioids to manage their pain. Acura is focused on developing technologies that are intended to potentially deter abuse and misuse.”

Based in Palatine, Ill., Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and commercialization of product candidates intended potentially to deter abuse and misuse utilizing its proprietary AVERSION® and IMPEDE® technologies.

Takeover target Harbin Electric (HRBN) surges

Monday, June 20th, 2011

Harbin Electric (Nasdaq: HRBN) shares rose more than 46% to $12.25 on Monday after the company agreed to be bought for $24 a share. A group led by Harbin’s CEO is doing the buying. Harbin Electric said it expects the deal to close in the fourth quarter. Volume for the stock totaled 6.8 million shares, more than five times its all-day average.

The company announced that it has entered into a definitive agreement and plan of merger with Tech Full Electric Company Limited, a Cayman Islands company wholly owned indirectly by Tianfu Yang, the Company’s Chairman and Chief Executive Officer, and Tech Full Electric Acquisition, Inc., a Nevada corporation wholly owned by Parent.

In the June 20 news release regarding the merger, Yang said, “I want to thank the Special Committee for its extremely thorough work in reviewing our offer to take the Company private in order to ensure that the interests of all shareholders of the Company are fully protected.

“I have full confidence that, with the help of its highly respected financial and legal advisors, the Special Committee has thoroughly reviewed and evaluated potential alternatives and has established the credibility of our offer, including the availability of debt financing from China Development Bank Corporation Hong Kong Branch and Abax.”

Harbin Electric, headquartered in Harbin, China, is a leading developer and manufacturer of a wide array of electric motors with a focus on innovative, customized, and value-added products.